Shares of Solaris Resources Inc. (CVE:SLS – Get Free Report) fell 2.7% on Thursday . The stock traded as low as C$5.95 and last traded at C$6.15. 53,313 shares changed hands during trading, a decline of 60% from the average daily volume of 132,199 shares. The stock had previously closed at C$6.32.
Solaris Resources Trading Down 2.7%
The stock has a fifty day moving average price of C$6.15 and a two-hundred day moving average price of C$6.15.
Solaris Resources Company Profile
SELLAS Life Sciences Group, Inc, a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer.
Further Reading
- Five stocks we like better than Solaris Resources
- Netflix May Be Cheap Enough to Tempt Buyers After Earnings Drop
- Delta vs. United: Which Airline Is Better Built for Higher Fuel Costs?
- The Market Sold Alcoa After Earnings—But It May Be Missing the Real Story
- Why Intuitive Surgical’s Strong Quarter Still Spooked Investors
Receive News & Ratings for Solaris Resources Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solaris Resources and related companies with MarketBeat.com's FREE daily email newsletter.
